Literature DB >> 28765885

Anti-angiogenic properties of artemisinin derivatives (Review).

Tianshu Wei1, Ju Liu2.   

Abstract

Angiogenesis, the process involving the development of new blood vessels from existing capillaries, is critical for growth and wound healing. However, pathological angiogenesis contributes to the pathogeneses of numerous diseases, including cancer, rheumatoid arthritis, diabetic retinopathy and macular degeneration. Hence, the inhibition of angiogenesis is an effective therapeutic approach for these diseases. Apart from its anti-malarial properties, artemisinin and its derivatives also exhibit potent anti-angiogenic properties. The molecular mechanisms underlying their inhibitory effects on angiogenesis have been studied by several groups. These investigations have revealed that artemisinins inhibit angiogenesis via the perturbations of cellular signaling pathways involved in the regulation of angiogenesis. Along with a brief introduction to artemisinin derivatives, this review provides a detailed summary of the effects of artemisinins on the mitogen-activated protein kinase (MAPK) pathway, the nuclear factor-κB (NF-κB) pathway and the phosphatidylinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway. Due to the multiplicity of their actions on relevant signaling pathways, artemisinins are promising candidates with potential for use as anti-angiogenic agents for the treatment of related diseases or disorders.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28765885     DOI: 10.3892/ijmm.2017.3085

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

Review 1.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

Review 2.  Potential applications of artemisinins in ocular diseases.

Authors:  Bing-Wen Lu; Li-Ke Xie
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

Review 3.  Artemisinin-type drugs for the treatment of hematological malignancies.

Authors:  R I Mancuso; M A Foglio; S T Olalla Saad
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-03       Impact factor: 3.333

4.  Dihydroartemisinin Induces Endothelial Cell Autophagy through Suppression of the Akt/mTOR Pathway.

Authors:  Jing Liu; Yanjun Ren; Yinglong Hou; Caiqing Zhang; Bei Wang; Xiaorui Li; Rong Sun; Ju Liu
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

5.  Dihydroartemisinin inhibits endothelial cell migration via the TGF-β1/ALK5/SMAD2 signaling pathway.

Authors:  Ling Guo; Xiaoqing Wen; Yinglong Hou; Rong Sun; Liang Zhang; Fuhong Liu; Ju Liu
Journal:  Exp Ther Med       Date:  2021-05-03       Impact factor: 2.447

6.  Dihydroartemisinin enhances VEGFR1 expression through up-regulation of ETS-1 transcription factor.

Authors:  Na Niu; Changmei Yu; Liqun Li; Qiang Liu; Wenqian Zhang; Kaili Liang; Youming Zhu; Jing Li; Xia Zhou; Jinbao Tang; Ju Liu
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

7.  Dihydroartemisinin Prevents Distant Metastasis of Laryngeal Carcinoma by Inactivating STAT3 in Cancer Stem Cells.

Authors:  Weiyi Wang; Yajing Sun; Xiaoming Li; Xinli Shi; Zhen Li; Xiuying Lu
Journal:  Med Sci Monit       Date:  2020-03-16

8.  Dihydroartemisinin inhibits the expression of von Willebrand factor by downregulation of transcription factor ERG in endothelial cells.

Authors:  Fengyun Dong; Xinghai Zhao; Jianning Wang; Xin Huang; Xiao Li; Liang Zhang; Haixin Dong; Fuhong Liu; Mengge Fan
Journal:  Fundam Clin Pharmacol       Date:  2020-11-07       Impact factor: 2.748

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.